Anticoagulation Management Directive Page 1						
Title:	Anticoagulation Management Directive		Number:	Anticoag1		
Activation Date:	February 18, 2009			Review due by:	Peter Dumo, Pharm.D.	
Sponsoring/Contact Person(s) (name, position, contact particulars):		Peter Dumo, Pharm.D. Clinical Pharmacist/Manager Novacare Pharmacy 1275 Walker Rd Windsor, ON 519-946-0303				
			Γ			
Order and/or Delegated Procedure:			Appendix Attached: Yes No Title: Novacare Pharmacy Anticoagulation Practice Referral Form			
Peter Dumo and pharmacists at Novacare Pharmacy are authorized to initiate, stop adjust, and modify medications for management of said patients anti-thrombotic management. These agents include warfarin, tinzaparin, enoxaparin, dalteparin, fondaprinux, and dabigatran.						
Peter Dumo and pharmacists at Novacare Pharmacy are authorized to carry out point-of-care based INR testing. Peter Dumo and pharmacists at Novacare are authorized to order the following laboratory tests by venous draw if and when required (PT/INR, BUN/Cr, Hgb/Hct, liver function tests and liver enzymes, anti-Xa levels (for purpose of LMWH monitoring).						
Dose of warfarin will be based on patient's INR, disease states, target range, nutritional status and concommitent medication.						
Initiation or cessation of LMWHs and dabigatran will be determined in conjunction with the referring physician. Dosing of these agents will be based on patient's height, weight, renal function, hepatic function and indication for anticoagulation.						
Goals for therapy and types of therapies that can be implemented/modified will be noted on the referal form for each patient. (see attached referral form)						
Recipient Patients:			Appendix Attached: ☐ Yes ☐ No Title:			
This medical directive applies be willing to receive clinical se					anagement services. Patients must nis directive to apply.	
Authorized Implementers:			Appendix Attached:			
The authorized implementers for this directive are Peter Dumo and any pharmacist at Novacare Pharmacy that Mr. Dumo assesses as competent to provide these services.						

Appendix Attached: ☐ Yes ☐ No

Title:

Indications:

This directive is indicated in patients referred by a physici	an foranticoagulation management services.				
Contraindications: Any patient refusing this model of care or consent for thes	se services				
Consent:	Appendix Attached: Yes No Title:				
	I appointment with Novacare Pharmacy staff. Consent may be				
Guidelines for Implementing the Order / Procedure:	Appendix Attached: Yes No Title:Novacare Pharmacy Outpatient Anticoagulation Protocol for Provision of Care				
Peter Dumo and any other pharamcists at Novacare Phara	macy will use the Amercian Society of Chest Physician Guidelines (Chest ulation Protocol for Provision of Care, sound clinical judgement and the				
Documentation and Communication:	Appendix Attached: ☐ Yes ☐ No Title:				
A progress note will be faxed/delivered to the referring physician with each patient visit. An abbreviated note/fax may be sent to accompany any over-the-phone titration/management.					
Review and Quality Monitoring Guidelines:	Appendix Attached: ☐ Yes ☐ No Title:				
Referring physicians will periodically review patient outcomes and identify any quality/care issues associated with the medical directive and patients receiving care via the directive. Any quality issues will be communicated to Peter Dumo.					
The Medical Director for this service will receive a quarte	rly report detailing:				
percent of INR's in range percent of INR greater than 6 or less than 1.5 thrombotic episode bleeding episodes					
Administrative Approvals (as applicable):	Appendix Attached: ☐ Yes ☐ No Title:				
None required					
Approving Physician(s)/Authorizer(s):	Appendix Attached: ☐ Yes ☐ No Title:				